These data suggest that SOX2 expression is an early event during tumorigenesis rather than a genetic event acquired during tumor progression, similar to our observations in breast cancer where aberrant SOX2 expression was already observed in the earliest stages of tumor development [11]. This evidence concerns the gene SOX2 and breast carcinoma.